Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Diagnostic procedures, such as positron emission tomography/computed tomography (PET/CT) scanning before surgery, may help measure the extent of disease.
PURPOSE: This clinical trial is studying PET/CT scanning before surgery in patients with non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, or head and neck cancer.
| Condition | Intervention |
|---|---|
|
Breast Cancer Colorectal Cancer Esophageal Cancer Head and Neck Cancer Lung Cancer |
Other: 18F-fluoromisonidazole Other: fluorescence angiography Other: laboratory biomarker analysis Procedure: infrared thermography Procedure: magnetic resonance imaging Procedure: therapeutic conventional surgery Radiation: [18F]-ML-10 Radiation: fludeoxyglucose F 18 Radiation: rubidium Rb-82 |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Diagnostic |
| Official Title: | Tumor Angiogenesis in Non-Small Cell Lung (NSCLC), Colorectal, Breast, Esophageal, Head and Neck Cancer: Radiology-Pathology and Prognostic Correlation |
- Clinical, radiological, and pathological correlation [ Designated as safety issue: No ]
- Prognosis (6-month, 1-year, 3-year, and 5-year mortality including local/distance recurrence rates) [ Designated as safety issue: No ]
| Estimated Enrollment: | 500 |
| Study Start Date: | November 2006 |
| Estimated Primary Completion Date: | August 2013 (Final data collection date for primary outcome measure) |
OBJECTIVES:
- To determine the ability of preoperative fludeoxyglucose F 18 positron emission tomography/computed tomography (PET/CT) scanning in assessing tumor angiogenesis in patients with potentially operable non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, or head and neck cancer.
- To determine the ability of preoperative fludeoxyglucose F 18 PET/CT scanning in assessing prognosis by means of measuring angiogenesis in these patients.
OUTLINE: All patients undergo fludeoxyglucose F 18 positron emission tomography/computed tomography (PET/CT) scanning for staging, tumor perfusion measurement/angiogenesis, and glucose metabolism. If staging confirms operable disease, then the patient proceeds to surgery as planned. Resected tumor tissue samples are examined for tumor angiogenesis in the various cancer types.
Some patients undergo a half-dose of rubidium Rb-82 or 18F-fluoromisonidazole or [18F]-ML-10 PET scan or fluorescence angiography. Patients with colorectal cancer undergo a CT scan for perfusion of the tumor after the staging PET/CT. Patients with breast cancer undergo infrared thermometry as well as a MRI scan for staging and to predict angiogenesis.
After completion of study therapy, patients are followed up at 1 month and then every 6 months for 5 years.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, or head and neck cancer
- Potentially operable disease
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Not specified
- Menopausal status not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Contacts and Locations| United Kingdom | |
| University College Hospital | Recruiting |
| London, England, United Kingdom, NW1 2BU | |
| Contact: Contact Person 44-207-631-1066 peter.ell@uclh.nhs.uk | |
| Principal Investigator: | Peter Ell, MD | University College London Hospitals |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT01254591 History of Changes |
| Other Study ID Numbers: | CDR0000689973, UCL-TUMOR-ANGIOGENESIS, EU-21086 |
| Study First Received: | December 3, 2010 |
| Last Updated: | February 26, 2011 |
| Health Authority: | Unspecified |
Keywords provided by National Cancer Institute (NCI):
|
stage IA non-small cell lung cancer stage IB non-small cell lung cancer stage IIA non-small cell lung cancer stage IIB non-small cell lung cancer stage IIIA non-small cell lung cancer stage I colon cancer stage IIA colon cancer stage IIB colon cancer stage IIC colon cancer stage IIIA colon cancer stage I rectal cancer stage IIA rectal cancer stage IIB rectal cancer stage IIC rectal cancer stage IIIA rectal cancer |
stage IA breast cancer stage IB breast cancer stage II breast cancer stage IIIA breast cancer stage IIIB breast cancer stage I esophageal cancer stage II esophageal cancer stage III esophageal cancer stage I hypopharyngeal cancer stage II hypopharyngeal cancer stage III hypopharyngeal cancer stage I laryngeal cancer stage II laryngeal cancer stage III laryngeal cancer stage I lip and oral cavity cancer |
Additional relevant MeSH terms:
|
Breast Neoplasms Carcinoma, Non-Small-Cell Lung Colorectal Neoplasms Esophageal Diseases Esophageal Neoplasms Head and Neck Neoplasms Lung Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms |
Lung Diseases Respiratory Tract Diseases Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Fluoromisonidazole Radiation-Sensitizing Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 22, 2013